Drug intelligence / Profile preview

iChondrocytes

Development stage: Preclinical
Lead developer: Factor Bioscience
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intraarticular, Implantation

Overview

iChondrocytes is an autologous cell therapy candidate being developed by Factor Biosciences. The therapy utilizes induced pluripotent stem cells (iPSCs) that are differentiated into chondrocytes using the company's proprietary mRNA-based cellular reprogramming and gene-editing technologies. iChondrocytes is intended to treat various conditions characterized by cartilage degradation or injury, such as osteoarthritis or focal cartilage defects, by providing a source of patient-specific cells for cartilage regeneration. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on iChondrocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iChondrocytes.

Explore the full profile